| Identification | Back Directory | [Name]
NSC 697726 | [CAS]
221635-42-3 | [Synonyms]
RH1
NSC 697726
2,5-Di(1-aziridinyl)-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone
2,5-Bis(1-aziridinyl)-3-(hydroxymethyl)-6-methyl-2,5-cyclohexadiene-1,4-dione
2,5-bis(aziridin-1-yl)-3-(hydroxymethyl)-6-methylcyclohexa-2,5-diene-1,4-dione
2,5-Cyclohexadiene-1,4-dione, 2,5-bis(1-aziridinyl)-3-(hydroxymethyl)-6-methyl- | [Molecular Formula]
C12H14N2O3 | [MDL Number]
MFCD11040853 | [MOL File]
221635-42-3.mol | [Molecular Weight]
234.25 |
| Hazard Information | Back Directory | [Uses]
RH1 (NSC 697726) is a potent bioreductive agent with profound anti-cancer activity in vitro and in vivo. | [in vivo]
RH1 exhibits antitumor activity in a dose-dependent manner against NQ16 tumors growing in athymic mice. RH1 treatment (0.4 mg/kg and 0.2 mg/kg) of mice bearing NQ16 tumors results in a significant reduction in tumor volume between treated groups and controls as early as 5 days after the treatment period ended. Low-dose RH1 (0.1 mg/kg) also results in a significant reduction in tumor volume between treated mice and controls[2]. | [References]
[1] Park MT, et al. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase. Br J Pharmacol. 2011 Jun;163(3):567-85. DOI:10.1111/j.1476-5381.2011.01233.x
[2] Dehn DL, et al. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. Clin Cancer Res. 2004 May 1;10(9):3147-55. DOI:10.1158/1078-0432.ccr-03-0411 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|